Drug Trial Radar · NCT03936153
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Jan 20, 2020
Primary completion
Jul 31, 2026
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Xynomic Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
abexinostatDrug
abexinostat tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical effect by evaluating the objective response rate (ORR)Time frame: up to 56 days
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Recruiting
China-Japan Friendship Hospital
Beijing, China · Recruiting
Peking University Third Hospital
Beijing, China · Recruiting
West China Hospital, Sichuan University
Chengdu, China · Recruiting
The First Affiliate Hospital of Dalian Medical University
Dalian, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, China · Recruiting
Fujian Provincial Cancer Hospital
Fuzhou, China · Recruiting
Cancer Center of Guangzhou Medical University
Guangzhou, China · Recruiting
Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University
Guangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
The Affiliated Tumor Hospital of Harbin Medical University
Harbin, China · Recruiting
The First Hospital of Lanzhou University
Lanzhou, China · Recruiting
Linyi Cancer Hospital
Linyi, China · Recruiting
Nantong Tumor Hospital
Nantong, China · Recruiting
Shanghai Jiao Tong University School Medicine
Shanghai, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Second People's Hospital of Shenzhen
Shenzhen, China · Recruiting
The Forth Hospital of Hebei Medical University
Shijiazhuang, China · Recruiting
First Hospital of Shanxi Medical University
Taiyuan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.